{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:14:28Z","timestamp":1794968068312,"version":"4.9.1"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Ocular surface events are a class effect of microtubule-inhibitor payload-containing antibody-drug conjugates (ADCs); the mechanism underlying these events has not been fully elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize corneal epithelial changes in patients with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin, a maleimidocaproyl monomethyl auristatin-F (MMAF)\u2013containing ADC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This multicenter, phase 3b case series study was conducted in the US from March 26, 2020, to November 21, 2022, among adults with RRMM. Data were analyzed from May 2021 to May 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Prior or ongoing treatment with belantamab mafodotin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point included pathologic characteristics and composition of corneal epithelial changes obtained by impression cytology (IC) or superficial keratectomy (SK) in patients treated with belantamab mafodotin. Tear film and blood were collected to determine belantamab mafodotin concentrations in patients at the time of sampling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 16 patients screened, 9 were included in this study, with 6 evaluable corneal samples obtained from 6 patients either by IC (n\u2009=\u20094) or SK (n\u2009=\u20092). Of 9 patients included, median (range) patient age was 67.0 (57.0-81.0) years for those with samples obtained by IC and 68.0 (65.0-81.0) years for those with samples obtained by SK. Six patients (67%) were female. All samples demonstrated epithelial cells with eosinophilic intracytoplasmic inclusions, basophilic granular cytoplasm, or both. Five samples were positive for apoptosis, and 3 samples showed evidence of inflammation. All patients experienced complete IC or SK wound healing. ADC was detected in the tear fluid of 5 of 7 patients with tear fluid sampling, while ADC was quantifiable in 3 of 4 patients with blood samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this case series study, intracytoplasmic inclusions were observed by histopathology in the corneal epithelium of patients exposed to belantamab mafodotin, and the pattern of corneal changes suggests limbal vessels may be a primary pathway enabling ADC to reach the cornea. Although limited to 6 samples, this study helps us better understand corneal changes associated with certain ADCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT04549363?cond=NCT04549363&amp;amp;amp;rank=1\">NCT04549363<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.1008","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T11:01:14Z","timestamp":1746702074000},"page":"507","source":"Crossref","is-referenced-by-count":16,"title":["Characterization of Belantamab Mafodotin\u2013Induced Corneal Changes in Patients With Multiple Myeloma"],"prefix":"10.1001","volume":"143","author":[{"given":"Vivian","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Petrone","sequence":"additional","affiliation":[{"name":"GSK, New Hope, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W.","family":"Lewis","sequence":"additional","affiliation":[{"name":"GSK, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Banna","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eben","family":"Lichtman","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praneetha","family":"Thulasi","sequence":"additional","affiliation":[{"name":"Emory University, Atlanta, Georgia"},{"name":"Now with Ophthalmology and Visual Sciences Division of Cornea and External Disease, Washington University Physicians, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjulie A.","family":"Quick","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Kansas Medical Center, Prairie Village"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennie H.","family":"Jeng","sequence":"additional","affiliation":[{"name":"Ophthalmology and Visual Sciences, University of Maryland, Baltimore"},{"name":"Now with Department of Ophthalmology and Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Sunshine","sequence":"additional","affiliation":[{"name":"Ophthalmology and Visual Sciences, University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine H.","family":"Francis","sequence":"additional","affiliation":[{"name":"Ophthalmic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Canestraro","sequence":"additional","affiliation":[{"name":"Ophthalmic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim V.","family":"Farooq","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Clements","sequence":"additional","affiliation":[{"name":"Pathology, Nonclinical Safety, GSK, Stevenage, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Robertson","sequence":"additional","affiliation":[{"name":"Nonclinical Safety, GSK, Stevenage, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Burman","sequence":"additional","affiliation":[{"name":"Formerly with Department of Genetic Toxicology, GSK, Ware, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"McKevitt","sequence":"additional","affiliation":[{"name":"Pathology, Nonclinical Safety, GSK, Stevenage, United Kingdom"},{"name":"Now with Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Struemper","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling & Simulation, GSK, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Weir","sequence":"additional","affiliation":[{"name":"Nonclinical Safety, GSK, Stevenage, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"eoi250018r1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"20","key":"eoi250018r2","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"10","key":"eoi250018r3","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo.","volume":"20","author":"Montes de Oca","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"61","key":"eoi250018r5","first-page":"19153","article-title":"Announcement of the revocation of the biologics license for BLENREP.","volume":"88","author":"Roth","year":"2023","journal-title":"Fed Regist"},{"issue":"5","key":"eoi250018r6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma.","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"eoi250018r7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2024-200336","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma: overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial.","volume":"144","author":"Hungria","year":"2024","journal-title":"Blood"},{"issue":"5","key":"eoi250018r8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma.","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"eoi250018r10","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","article-title":"Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma.","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"eoi250018r11","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.","volume":"32","author":"Tannir","year":"2014","journal-title":"Invest New Drugs"},{"issue":"7","key":"eoi250018r12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/neuonc\/now257","article-title":"Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.","volume":"19","author":"Reardon","year":"2017","journal-title":"Neuro Oncol"},{"issue":"6","key":"eoi250018r13","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine.","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"eoi250018r14","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1159\/000531142","article-title":"A phase 3b study for management of ocular side effects in patients with epidermal growth factor receptor-amplified glioblastoma receiving depatuxizumab mafodotin.","volume":"66","author":"Vize","year":"2023","journal-title":"Ophthalmic Res"},{"issue":"1","key":"eoi250018r15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41408-024-01110-x","article-title":"Dynamics of microcyst-like epithelial changes associated with belantamab mafodotin therapy in a patient with multiple myeloma-a case report.","volume":"14","author":"Schloesser","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"eoi250018r16","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates.","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"issue":"6","key":"eoi250018r17","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","article-title":"Antibody-drug conjugates for the treatment of non-Hodgkin\u2019s lymphoma: target and linker-drug selection.","volume":"69","author":"Polson","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"eoi250018r18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"6","key":"eoi250018r19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10928-016-9495-8","article-title":"Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.","volume":"43","author":"Singh","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"eoi250018r20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2022.06.009","article-title":"Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: neuropathy studied with confocal microscopy.","volume":"242","author":"Aschauer","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"eoi250018r21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates.","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"4","key":"eoi250018r22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study.","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"eoi250018r23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"issue":"9","key":"eoi250018r24","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1097\/ICO.0000000000002595","article-title":"Clinical and histological characterization of toxic keratopathy from depatuxizumab mafodotin (ABT-414), an antibody-drug conjugate.","volume":"40","author":"Lee","year":"2021","journal-title":"Cornea"},{"issue":"12","key":"eoi250018r25","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.ophtha.2020.07.047","article-title":"Belantamab mafotodin-induced epithelial keratopathy masquerading myopic surgery.","volume":"127","author":"Rousseau","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi250018r26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/ICO.0000000000002934","article-title":"Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates.","volume":"41","author":"Canestraro","year":"2022","journal-title":"Cornea"},{"issue":"6","key":"eoi250018r27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/ICL.0000000000000768","article-title":"Corneal changes after belantamab mafodotin in multiple myeloma patients.","volume":"47","author":"Bausell","year":"2021","journal-title":"Eye Contact Lens"},{"key":"eoi250018r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101133","article-title":"Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.","volume":"23","author":"Matsumiya","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"11","key":"eoi250018r29","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1007\/s00417-023-06094-1","article-title":"Ocular surface changes associated with belantamab mafodotin treatment.","volume":"261","author":"Ghalibafan","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"eoi250018r30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2010.08.047","article-title":"Appropriate use and reporting of uncontrolled case series in the medical literature.","volume":"151","author":"Kempen","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi250018r31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/10428194.2023.2273746","article-title":"Clinical characteristics, treatment patterns, and outcomes among African American and White patients with multiple myeloma in the United States.","volume":"65","author":"Saunders","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"eoi250018r32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/cncy.22384","article-title":"Ocular cytology: diagnostic features and ongoing practices.","volume":"129","author":"Laver","year":"2021","journal-title":"Cancer Cytopathol"},{"issue":"12","key":"eoi250018r33","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1136\/bjo.2005.073916","article-title":"Impression cytology of the ocular surface.","volume":"89","author":"Singh","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi250018r34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconjug Chem"},{"key":"eoi250018r4","unstructured":"European Medicines Agency. EMA confirms recommendation for non-renewal of authorisation of multiple myeloma medicine Blenrep. Accessed December 9, 2024. https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-recommendation-non-renewal-authorisation-multiple-myeloma-medicine-blenrep"},{"key":"eoi250018r9","unstructured":"GSK. Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse. Accessed December 13, 2024. https:\/\/www.gsk.com\/media\/11702\/blenrep-dreamm-7-os-full-data-press-release_final.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2833594\/jamaophthalmology_lee_2025_oi_250018_1749757316.59475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:00:39Z","timestamp":1750417239000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2833594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.1008","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}